HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Topical Sirolimus for Microcystic Lymphatic Malformations
This study is now recruiting.
The purpose of this study is to see if a new topical (applied to the skin) formulation of rapamycin, PTX-022, is safe and effective in treating participants with microcystic Lymphatic Malformations (mLM).
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at cvapresearch [at] chop.edu or 267-426-0743.
Eligibility & Criteria
The purpose of this study is to evaluate the safety and tolerability of the study drug PTX-022. The study will enroll male and female patients between 13 and 60 years of age that have been diagnosed with a microcystic lymphatic malformation with a history of frequent leaking and/or bleeding. Subjects will receive PTX-022, which is a topical gel that will be applied directly to the lesion. Participation will last for about 20 weeks and will include 8 visits. Study visits include the following assessments: physical exams, vital signs, blood and urine tests, photography of the lesions, and the completion of diaries and questionnaires. Reimbursement for travel expenses and compensation for participation may be provided.